Home › Compare › IMHDF vs ABBV
IMHDF yields 2.08% · ABBV yields 3.06%● Live data
📍 IMHDF pulled ahead of the other in Year 4
Combined, IMHDF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of IMHDF + ABBV for your $10,000?
Isetan Mitsukoshi Holdings Ltd., together with its subsidiaries, engages in the department store business in Japan and internationally. The company operates through Department Store Business, Credit & Finance Business/Customer Organization Management Business, Real Estate Business, and Other Business segments. It is involved in the credit card, insurance, and other businesses; constructs and manages underground garages, public underground passages, and underground shopping malls; leases shops; operates restaurants; operates shares and business management; and construction and design, construction management, renovation and interior furniture, building maintenance, and environment production businesses. The company also engages in the supermarket, retail, and specialty shops; food production; wholesaling business; the operation of airport-style duty free shops; and provision of personnel, employment agency, recruitment office, education and training, and labor and welfare services, as well as information systems solutions. In addition, it plans, develops, imports, and sells gifts, novelty, and lifestyle goods; imports and wholesales western wine and spirits, foods, and miscellaneous products; and sells foodstuffs, clothing, and other daily goods. Further, the company plans, produces, promotes, and sells commercials, video signs, TV programs, movies, plays, entertainment and fashion shows, parties, etc.; engages in advertising agency business; plans and sells travel products and conducts tours; and owns and operates river cruise ships. The company was incorporated in 2008 and is headquartered in Tokyo, Japan.
Full IMHDF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.